View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 4, 2022

Curis’ oral cancer therapy trial receives FDA partial clinical hold

The latest development comes after the company reported the death of a patient with R/R AML.

Curis’ Phase I/IIa TakeAim Leukemia clinical trial of emavusertib (CA-4948) for acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS) was placed on a partial clinical hold by the US Food and Drug Administration (FDA).

With the latest development, the regulatory agency has sought further data from the trial, including those linked to the death of a subject with relapsed or refractory (R/R) AML.

The trial will not enrol new participants while the presently enrolled subjects who benefit from the therapy could continue to receive 300mg twice daily or lower doses of emavusertib. Emavusertib is an inhibitor of IRAK4 kinase.

The open-label, single-arm dose escalation and expansion trial is designed to assess the oral dose of emavusertib as a single agent and along with azacitidine or venetoclax in R/R AML or high-risk MDS patients.

Curis noted that the patient under question had various conditions, including rhabdomyolysis, which was earlier classified as emavusertib’s dose-limiting toxicity. 

Furthermore, the FDA is seeking safety, efficacy and other findings, including data linked to rhabdomyolysis and the identification of the recommended Phase II dose of emavusertib in the trial.

On FDA lifting the partial clinical hold and the linked impact on the study is evaluated, Curis anticipates to provide the updated guidance on the timing of talks with the regulatory authority to seek registration for emavusertib.

Curis CEO James Dentzer said: “We are committed to ensuring the safety of patients in our studies and to working collaboratively with the FDA to develop therapies that meaningfully improve and extend patients’ lives. 

“Given the clinical profile of emavusertib observed to date, we are hopeful that the study can be resumed soon, after appropriate review.”

The latest move will not impact another open-label, dose-escalating Phase I/II TakeAim Lymphoma study but Curis will halt new subject enrolment in this trial. 

The TakeAim Lymphoma study is assessing emavusertib in people with B-cell malignancies.

In February last year, Curis dosed the first subject in Phase I trial of CA-4948 plus ibrutinib in individuals with R/R hematologic malignancies.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy